CytomX Therapeutics, Inc.
General ticker "CTMX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $140.8M (TTM average)
CytomX Therapeutics, Inc. follows the US Stock Market performance with the rate: 51.7%.
Estimated limits based on current volatility of 4.6%: low 3.90$, high 4.27$
Factors to consider:
- Total employees count: 119 (-2.5%) as of 2024
- Top business risk factors: Insufficient funding, Third-party risks, Climate change and natural disasters, Operational and conduct risks, Acquisition/divestiture risks
- Current price 115.6% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.68$, 1.89$]
- 2025-12-31 to 2026-12-31 estimated range: [0.78$, 2.10$]
Financial Metrics affecting the CTMX estimates:
- Positive: with PPE of 2.8 at the end of fiscal year the price was very low
- Positive: 7.86 < Operating profit margin, % of 18.10
- Negative: Operating cash flow per share per price, % of -95.14 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 20.91 > 6.04
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CTMX quotes
Long-term CTMX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $53.16MM | $101.21MM | $138.10MM |
| Operating Expenses | $154.50MM | $107.70MM | $113.11MM |
| Operating Income | $-101.33MM | $-6.48MM | $25.00MM |
| Non-Operating Income | $2.02MM | $9.81MM | $7.10MM |
| R&D Expense | $111.65MM | $77.68MM | $83.38MM |
| Income(Loss) | $-99.32MM | $3.32MM | $32.09MM |
| Taxes | $0.00MM | $3.89MM | $0.22MM |
| Profit(Loss)* | $-99.32MM | $-0.57MM | $31.87MM |
| Stockholders Equity | $-85.75MM | $-47.45MM | $-0.46MM |
| Assets | $260.89MM | $201.79MM | $120.53MM |
| Operating Cash Flow | $-110.79MM | $-56.03MM | $-86.23MM |
| Capital expenditure | $1.74MM | $0.84MM | $0.31MM |
| Investing Cash Flow | $98.26MM | $-150.67MM | $99.70MM |
| Financing Cash Flow | $0.65MM | $30.23MM | $7.52MM |
| Earnings Per Share** | $-1.51 | $-0.01 | $0.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.